Phase 2 Study of Vinblastine in Children With Recurrent or Refractory Low Grade Glioma

Inclusion Criteria: < 21 years of age at original diagnosis histological verification of low grade glioma (glial tumors, neuronal tumors or chiasmatic-hypothalamic tumor) at original diagnosis evidence of tumor recurrence or progression by MRI or contrast CT Karnofsky and Lansky performance status of 0,1 or 2 life expectancy of greater than or equal to 2 months adequate organ and bone marrow function within 7 days of starting treatment with Vinblastine absolute neutrophil count (ANC)> 1000/uL platelet count > 100,000/uL (transfusion independent) serum creatinine < 1.5 x normal for age written informed consent signed by subject and/or subject's parent/legal guardian Exclusion Criteria: not recovered from the acute toxic effects of all prior chemotherapy, immunotherapy or radiotherapy chemotherapy within 2 weeks of entry in study (4 weeks if prior nitrosourea was used) less than 7 days since the completion of therapy with a biologic agent less than 2 months since cranial/spinal radiation receiving a stable dose of dexamethasone for less than one week